EyePoint Pharmaceuticals (EYPT) Misses Q2 EPS by 4c

EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q2 EPS of ($0.85), $0.04 worse than the analyst estimate of ($0.81). Revenue for the quarter came in at $5.3 million versus the consensus estimate of $6.66 million.

For earnings history and earnings-related data on EyePoint Pharmaceuticals (EYPT) click here.

You May Also Be Interested In

• Phillip Securities Reiterates Buy Rating on Sea Ltd. (SE)
• Faraday Future reports record Q2 revenue, cuts debt by $100M
• Rocket Lab Satellite Platforms Built for MDA Space Successfully Reach Orbit